Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations.

[en] Cancer and cardiovascular (CV) disease are the most prevalent diseases in the developed world. Evidence increasingly shows that these conditions are interlinked through common risk factors, coincident in an ageing population, and are connected biologically through some deleterious effects of anticancer treatment on CV health. Anticancer therapies can cause a wide spectrum of short- and long-term cardiotoxic effects. An explosion of novel cancer therapies has revolutionised this field and dramatically altered cancer prognosis. Nevertheless, these new therapies have introduced unexpected CV complications beyond heart failure. Common CV toxicities related to cancer therapy are defined, along with suggested strategies for prevention, detection and treatment. This ESMO consensus article proposes to define CV toxicities related to cancer or its therapies and provide guidance regarding prevention, screening, monitoring and treatment of CV toxicity. The majority of anticancer therapies are associated with some CV toxicity, ranging from asymptomatic and transient to more clinically significant and long-lasting cardiac events. It is critical however, that concerns about potential CV damage resulting from anticancer therapies should be weighed against the potential benefits of cancer therapy, including benefits in overall survival. CV disease in patients with cancer is complex and treatment needs to be individualised. The scope of cardio-oncology is wide and includes prevention, detection, monitoring and treatment of CV toxicity related to cancer therapy, and also ensuring the safe development of future novel cancer treatments that minimise the impact on CV health. It is anticipated that the management strategies discussed herein will be suitable for the majority of patients. Nonetheless, the clinical judgment of physicians remains extremely important; hence, when using these best clinical practices to inform treatment options and decisions, practitioners should also consider the individual circumstances of their patients on a case-by-case basis.

Disciplines :

Cardiovascular & respiratory systems

Author, co-author :

Curigliano, Giuseppe

Lenihan, Daniel J.

Fradley, Michael G.

Ganatra, Sarju

Barac, A.

Blaes, A.

Herrmann, J.

Porter, C.

Lyon, A. R.

Lancellotti, Patrizio ; Université de Liège - ULiège > Département des sciences cliniques > Cardiologie - Pathologie spéciale et réhabilitation

More authors (19 more)

Language :

English

Title :

Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations.

Publication date :

2020

Journal title :

Annals of Oncology: Official Journal of the European Society for Medical Oncology

ISSN :

0923-7534

eISSN :

1569-8041

Volume :

Issue :

Pages :

171-190

Peer reviewed :

Peer reviewed

Commentary :

Available on ORBi :

since 03 February 2020

Statistics

Number of views

487 (6 by ULiège)

Number of downloads

684 (5 by ULiège)

More statistics

Scopus citations^®

682

Scopus citations^®
without self-citations

572

OpenCitations

371

OpenAlex citations

756

Bibliography

Jones, D.S., Podolsky, S.H., Greene, J.A., The burden of disease and the changing task of medicine. N Engl J Med 366 (2012), 2333–2338.
Lee, L., Cheung, W.Y., Atkinson, E., et al. Impact of comorbidity on chemotherapy use and outcomes in solid tumors: a systematic review. J Clin Oncol 29 (2011), 106–117.
Coleman, M.P., Cancer survival: global surveillance will stimulate health policy and improve equity. Lancet 383 (2014), 564–573.
Lenihan, D.J., Cardinale, D.M., Late cardiac effects of cancer treatment. J Clin Oncol 30 (2012), 3657–3664.
Darby, S.C., Ewertz, M., McGale, P., et al. Risk of ischemic heart disease in women after radiotherapy for breast cancer. N Engl J Med 368 (2013), 987–998.
Verma, S., Ewer, M.S., Is cardiotoxicity being adequately assessed in current trials of cytotoxic and targeted agents in breast cancer?. Ann Oncol 22 (2011), 1011–1018.
Dykewicz, C.A., Summary of the guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients. Clin Infect Dis 33 (2001), 139–144.
Goff, D.C. Jr., Lloyd-Jones, D.M., Bennett, G., et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 63 (2014), 2935–2959.
Stone, N.J., Robinson, J.G., Lichtenstein, A.H., et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 63 (2014), 2889–2934.
Lloyd-Jones, D.M., Goff, D., Stone, N.J., Statins, risk assessment, and the new American prevention guidelines. Lancet 383 (2014), 600–602.
Armstrong, G.T., Oeffinger, K.C., Chen, Y., et al. Modifiable risk factors and major cardiac events among adult survivors of childhood cancer. J Clin Oncol 31 (2013), 3673–3680.
Mulrooney, D.A., Armstrong, G.T., Huang, S., et al. Cardiac outcomes in adult survivors of childhood cancer exposed to cardiotoxic therapy: A cross-sectional study. Ann Intern Med 164 (2016), 93–101.
Curigliano, G., Cardinale, D., Suter, T., et al. Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO Clinical Practice Guidelines. Ann Oncol 23:suppl 7 (2012), vii155–vii166.
Armenian, S.H., Xu, L., Ky, B., et al. Cardiovascular disease among survivors of adult-onset cancer: a community-based retrospective cohort study. J Clin Oncol 34 (2016), 1122–1130.
Armenian, S.H., Sun, C.L., Vase, T., et al. Cardiovascular risk factors in hematopoietic cell transplantation survivors: role in development of subsequent cardiovascular disease. Blood 120 (2012), 4505–4512.
Leger, K.J., Baker, K.S., Cushing-Haugen, K.L., et al. Lifestyle factors and subsequent ischemic heart disease risk after hematopoietic cell transplantation. Cancer 124 (2018), 1507–1515.
Chow, E.J., Baker, K.S., Lee, S.J., et al. Influence of conventional cardiovascular risk factors and lifestyle characteristics on cardiovascular disease after hematopoietic cell transplantation. J Clin Oncol 32 (2014), 191–198.
Slamon, D., Eiermann, W., Robert, N., et al. Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med 365 (2011), 1273–1283.
Stewart, A.K., Rajkumar, S.V., Dimopoulos, M.A., et al. Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. N Engl J Med 372 (2015), 142–152.
Moslehi, J.J., Cardiovascular toxic effects of targeted cancer therapies. N Engl J Med 375 (2016), 1457–1467.
Postow, M.A., Sidlow, R., Hellmann, M.D., Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med 378 (2018), 158–168.
Hall, P.S., Harshman, L.C., Srinivas, S., et al. The frequency and severity of cardiovascular toxicity from targeted therapy in advanced renal cell carcinoma patients. JACC Heart Fail 1 (2013), 72–78.
Li, W., Croce, K., Steensma, D.P., et al. Vascular and metabolic implications of novel targeted cancer therapies: focus on kinase inhibitors. J Am Coll Cardiol 66 (2015), 1160–1178.
Taylor, C., Correa, C., Duane, F.K., et al. Estimating the risks of breast cancer radiotherapy: evidence from modern radiation doses to the lungs and heart and from previous randomized trials. J Clin Oncol 35 (2017), 1641–1649.
Simone, C.B. 2nd, New era in radiation oncology for lung cancer: recognizing the importance of cardiac irradiation. J Clin Oncol 35 (2017), 1381–1383.
Dess, R.T., Sun, Y., Matuszak, M.M., et al. Cardiac events after radiation therapy: combined analysis of prospective multicenter trials for locally advanced non-small-cell lung cancer. J Clin Oncol 35 (2017), 1395–1402.
Groarke, J.D., Nguyen, P.L., Nohria, A., et al. Cardiovascular complications of radiation therapy for thoracic malignancies: the role for non-invasive imaging for detection of cardiovascular disease. Eur Heart J 35 (2014), 612–623.
Groarke, J.D., Tanguturi, V.K., Hainer, J., et al. Abnormal exercise response in long-term survivors of hodgkin lymphoma treated with thoracic irradiation: evidence of cardiac autonomic dysfunction and impact on outcomes. J Am Coll Cardiol 65 (2015), 573–583.
Copeland, K.A., Hosmane, V.R., Jurkovitz, C., et al. Frequency of severe valvular disease caused by mediastinal radiation among patients undergoing valve surgery in a community-based, regional academic medical center. Clin Cardiol 36 (2013), 217–221.
Heidenreich, P.A., Hancock, S.L., Lee, B.K., et al. Asymptomatic cardiac disease following mediastinal irradiation. J Am Coll Cardiol 42 (2003), 743–749.
Hull, M.C., Morris, C.G., Pepine, C.J., et al. Valvular dysfunction and carotid, subclavian, and coronary artery disease in survivors of hodgkin lymphoma treated with radiation therapy. JAMA 290 (2003), 2831–2837.
Jaworski, C., Mariani, J.A., Wheeler, G., et al. Cardiac complications of thoracic irradiation. J Am Coll Cardiol 61 (2013), 2319–2328.
Ammon, M., Arenja, N., Leibundgut, G., et al. Cardiovascular management of cancer patients with chemotherapy-associated left ventricular systolic dysfunction in real-world clinical practice. J Card Fail 19 (2013), 629–634.
Pituskin, E., Haykowsky, M., McNeely, M., et al. Rationale and design of the multidisciplinary team IntervenTion in cArdio-oNcology study (TITAN). BMC Cancer, 16, 2016, 733.
Guan, J., Khambhati, J., Jones, L.W., et al. Cardiology patient page. ABCDE steps for heart and vascular wellness following a prostate cancer diagnosis. Circulation 132 (2015), e218–e220.
Bhatia, N., Santos, M., Jones, L.W., et al. Cardiovascular effects of androgen deprivation therapy for the treatment of prostate cancer: ABCDE steps to reduce cardiovascular disease in patients with prostate cancer. Circulation 133 (2016), 537–541.
Mehta, L.S., Watson, K.E., Barac, A., et al. Cardiovascular disease and breast cancer: where these entities intersect: a scientific statement from the American Heart Association. Circulation 137 (2018), e30–e66.
Curigliano, G., Cardinale, D., Dent, S., et al. Cardiotoxicity of anticancer treatments: Epidemiology, detection, and management. CA Cancer J Clin 66 (2016), 309–325.
Lipshultz, S.E., Rifai, N., Sallan, S.E., et al. Predictive value of cardiac troponin T in pediatric patients at risk for myocardial injury. Circulation 96 (1997), 2641–2648.
Cardinale, D., Sandri, M.T., Martinoni, A., et al. Myocardial injury revealed by plasma troponin I in breast cancer treated with high-dose chemotherapy. Ann Oncol 13 (2002), 710–715.
Kilickap, S., Barista, I., Akgul, E., et al. cTnT can be a useful marker for early detection of anthracycline cardiotoxicity. Ann Oncol 16 (2005), 798–804.
Cornell, R.F., Ky, B., Weiss, B.M., et al. Prospective study of cardiac events during proteasome inhibitor therapy for relapsed multiple myeloma. J Clin Oncol 37 (2019), 1946–1955.
Cardinale, D., Sandri, M.T., Colombo, A., et al. Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy. Circulation 109 (2004), 2749–2754.
Ky, B., Putt, M., Sawaya, H., et al. Early increases in multiple biomarkers predict subsequent cardiotoxicity in patients with breast cancer treated with doxorubicin, taxanes, and trastuzumab. J Am Coll Cardiol 63 (2014), 809–816.
Zardavas, D., Suter, T.M., Van Veldhuisen, D.J., et al. Role of troponins I and T and N-terminal prohormone of brain natriuretic peptide in monitoring cardiac safety of patients with early-stage human epidermal growth factor receptor 2-positive breast cancer receiving trastuzumab: A herceptin adjuvant study cardiac marker substudy. J Clin Oncol 35 (2017), 878–884.
Cardinale, D., Colombo, A., Torrisi, R., et al. Trastuzumab-induced cardiotoxicity: clinical and prognostic implications of troponin I evaluation. J Clin Oncol 28 (2010), 3910–3916.
Fallah-Rad, N., Walker, J.R., Wassef, A., et al. The utility of cardiac biomarkers, tissue velocity and strain imaging, and cardiac magnetic resonance imaging in predicting early left ventricular dysfunction in patients with human epidermal growth factor receptor II-positive breast cancer treated with adjuvant trastuzumab therapy. J Am Coll Cardiol 57 (2011), 2263–2270.
Skovgaard, D., Hasbak, P., Kjaer, A., BNP predicts chemotherapy-related cardiotoxicity and death: comparison with gated equilibrium radionuclide ventriculography. PLoS One, 9, 2014, e96736.
Sawaya, H., Sebag, I.A., Plana, J.C., et al. Early detection and prediction of cardiotoxicity in chemotherapy-treated patients. Am J Cardiol 107 (2011), 1375–1380.
Lenihan, D.J., Stevens, P.L., Massey, M., et al. The utility of point-of-care biomarkers to detect cardiotoxicity during anthracycline chemotherapy: A feasibility study. J Card Fail 22 (2016), 433–438.
Roden, D.M., Drug-induced prolongation of the QT interval. N Engl J Med 350 (2004), 1013–1022.
Naing, A., Veasey-Rodrigues, H., Hong, D.S., et al. Electrocardiograms (ECGs) in phase I anticancer drug development: the MD Anderson Cancer Center experience with 8518 ECGs. Ann Oncol 23 (2012), 2960–2963.
Curigliano, G., Spitaleri, G., Fingert, H.J., et al. Drug-induced QTc interval prolongation: a proposal towards an efficient and safe anticancer drug development. Eur J Cancer 44 (2008), 494–500.
Borad, M.J., Soman, A.D., Benjamin, M., et al. Effect of selection of QTc formula on eligibility of cancer patients for phase I clinical trials. Invest New Drugs 31 (2013), 1056–1065.
Viganego, F., Singh, R., Fradley, M.G., Arrhythmias and other electrophysiology issues in cancer patients receiving chemotherapy or radiation. Curr Cardiol Rep, 18, 2016, 52.
Fradley, M.G., Moslehi, J., QT Prolongation and oncology drug development. Card Electrophysiol Clin 7 (2015), 341–355.
Hortobagyi, G.N., Stemmer, S.M., Burris, H.A., et al. Ribociclib as first-line therapy for HR-positive, advanced breast cancer. N Engl J Med 375 (2016), 1738–1748.
Shah, R.R., Morganroth, J., Shah, D.R., Cardiovascular safety of tyrosine kinase inhibitors: with a special focus on cardiac repolarisation (QT interval). Drug Saf 36 (2013), 295–316.
Turner, J.R., Panicker, G.K., Karnad, D.R., et al. Cardiovascular safety monitoring during oncology drug development and therapy. Am J Ther 21 (2014), 512–522.
Plana, J.C., Galderisi, M., Barac, A., et al. Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr 27 (2014), 911–939.
Eschenhagen, T., Force, T., Ewer, M.S., et al. Cardiovascular side effects of cancer therapies: a position statement from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail 13 (2011), 1–10.
Armenian, S.H., Lacchetti, C., Barac, A., et al. Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol 35 (2017), 893–911.
Hunt, S.A., Baker, D.W., Chin, M.H., et al. ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to revise the 1995 Guidelines for the Evaluation and Management of Heart Failure). J Am Coll Cardiol 38 (2001), 2101–2113.
Narayan, H.K., Finkelman, B., French, B., et al. Detailed echocardiographic phenotyping in breast cancer patients: associations with ejection fraction decline, recovery, and heart failure symptoms over 3 years of follow-up. Circulation 135 (2017), 1397–1412.
Cardinale, D., Colombo, A., Sandri, M.T., et al. Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition. Circulation 114 (2006), 2474–2481.
Kalay, N., Basar, E., Ozdogru, I., et al. Protective effects of carvedilol against anthracycline-induced cardiomyopathy. J Am Coll Cardiol 48 (2006), 2258–2262.
Bosch, X., Rovira, M., Sitges, M., et al. Enalapril and carvedilol for preventing chemotherapy-induced left ventricular systolic dysfunction in patients with malignant hemopathies: the OVERCOME trial (preventiOn of left Ventricular dysfunction with Enalapril and caRvedilol in patients submitted to intensive ChemOtherapy for the treatment of Malignant hEmopathies). J Am Coll Cardiol 61 (2013), 2355–2362.
Gulati, G., Heck, S.L., Ree, A.H., et al. Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): a 2 × 2 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol. Eur Heart J 37 (2016), 1671–1680.
Pituskin, E., Mackey, J.R., Koshman, S., et al. Multidisciplinary Approach to Novel Therapies in Cardio-Oncology Research (MANTICORE 101-Breast): a randomized trial for the prevention of trastuzumab-associated cardiotoxicity. J Clin Oncol 35 (2017), 870–877.
Avila, M.S., Ayub-Ferreira, S.M., de Barros Wanderley, M.R. Jr., et al. Carvedilol for prevention of chemotherapy-related cardiotoxicity: The CECCY trial. J Am Coll Cardiol 71 (2018), 2281–2290.
Guglin, M., Krischer, J., Tamura, R., et al. Randomized trial of lisinopril versus carvedilol to prevent trastuzumab cardiotoxicity in patients with breast cancer. J Am Coll Cardiol 73 (2019), 2859–2868.
Akpek, M., Ozdogru, I., Sahin, O., et al. Protective effects of spironolactone against anthracycline-induced cardiomyopathy. Eur J Heart Fail 17 (2015), 81–89.
Swain, S.M., Whaley, F.S., Gerber, M.C., et al. Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer. J Clin Oncol 15 (1997), 1318–1332.
van Dalen, E.C., Caron, H.N., Dickinson, H.O., et al. Cardioprotective interventions for cancer patients receiving anthracyclines. Cochrane Database Syst Rev, 1, 2005, CD003917.
Liesse, K., Harris, J., Chan, M., et al. Dexrazoxane significantly reduces anthracycline-induced cardiotoxicity in pediatric solid tumor patients: a systematic review. J Pediatr Hematol Oncol 40 (2018), 417–425.
Ganatra, S., Nohria, A., Shah, S., et al. Upfront dexrazoxane for the reduction of anthracycline-induced cardiotoxicity in adults with preexisting cardiomyopathy and cancer: a consecutive case series. Cardio-Oncol, 5, 2019, 1.
Tall, A.R., Levine, R.L., Cardiovascular disease: commonality with cancer. Nature 543 (2017), 45–47.
Seicean, S., Seicean, A., Plana, J.C., et al. Effect of statin therapy on the risk for incident heart failure in patients with breast cancer receiving anthracycline chemotherapy: an observational clinical cohort study. J Am Coll Cardiol 60 (2012), 2384–2390.
Acar, Z., Kale, A., Turgut, M., et al. Efficiency of atorvastatin in the protection of anthracycline-induced cardiomyopathy. J Am Coll Cardiol 58 (2011), 988–989.
McKay, R.R., Lin, X., Albiges, L., et al. Statins and survival outcomes in patients with metastatic renal cell carcinoma. Eur J Cancer 52 (2016), 155–162.
Walker, J., Bhullar, N., Fallah-Rad, N., et al. Role of three-dimensional echocardiography in breast cancer: comparison with two-dimensional echocardiography, multiple-gated acquisition scans, and cardiac magnetic resonance imaging. J Clin Oncol 28 (2010), 3429–3436.
Thavendiranathan, P., Grant, A.D., Negishi, T., et al. Reproducibility of echocardiographic techniques for sequential assessment of left ventricular ejection fraction and volumes: application to patients undergoing cancer chemotherapy. J Am Coll Cardiol 61 (2013), 77–84.
Dorosz, J.L., Lezotte, D.C., Weitzenkamp, D.A., et al. Performance of 3-dimensional echocardiography in measuring left ventricular volumes and ejection fraction: a systematic review and meta-analysis. J Am Coll Cardiol 59 (2012), 1799–1808.
Vasu, S., Hundley, W.G., Understanding cardiovascular injury after treatment for cancer: an overview of current uses and future directions of cardiovascular magnetic resonance. J Cardiovasc Magn Reson, 15, 2013, 66.
Burke, L.M., Bashir, M.R., Neville, A.M., et al. Current opinions on medical radiation: a survey of oncologists regarding radiation exposure and dose reduction in oncology patients. J Am Coll Radiol 11 (2014), 490–495.
Fazel, R., Krumholz, H.M., Wang, Y., et al. Exposure to low-dose ionizing radiation from medical imaging procedures. N Engl J Med 361 (2009), 849–857.
Hoffmann, R., von Bardeleben, S., ten Cate, F., et al. Assessment of systolic left ventricular function: a multi-centre comparison of cineventriculography, cardiac magnetic resonance imaging, unenhanced and contrast-enhanced echocardiography. Eur Heart J 26 (2005), 607–616.
Negishi, K., Negishi, T., Hare, J.L., et al. Independent and incremental value of deformation indices for prediction of trastuzumab-induced cardiotoxicity. J Am Soc Echocardiogr 26 (2013), 493–498.
Negishi, K., Negishi, T., Haluska, B.A., et al. Use of speckle strain to assess left ventricular responses to cardiotoxic chemotherapy and cardioprotection. Eur Heart J Cardiovasc Imaging 15 (2014), 324–331.
Sawaya, H., Sebag, I.A., Plana, J.C., et al. Assessment of echocardiography and biomarkers for the extended prediction of cardiotoxicity in patients treated with anthracyclines, taxanes, and trastuzumab. Circ Cardiovasc Imaging 5 (2012), 596–603.
Stoodley, P.W., Richards, D.A., Meikle, S.R., et al. The potential role of echocardiographic strain imaging for evaluating cardiotoxicity due to cancer therapy. Heart Lung Circ 20 (2011), 3–9.
Marwick, T.H., Leano, R.L., Brown, J., et al. Myocardial strain measurement with 2-dimensional speckle-tracking echocardiography: definition of normal range. JACC Cardiovasc Imaging 2 (2009), 80–84.
Sun, J.P., Popovic, Z.B., Greenberg, N.L., et al. Noninvasive quantification of regional myocardial function using Doppler-derived velocity, displacement, strain rate, and strain in healthy volunteers: effects of aging. J Am Soc Echocardiogr 17 (2004), 132–138.
Otterstad, J.E., Froeland, G., St John Sutton, M., et al. Accuracy and reproducibility of biplane two-dimensional echocardiographic measurements of left ventricular dimensions and function. Eur Heart J 18 (1997), 507–513.
Jordan, J.H., Sukpraphrute, B., Melendez, G.C., et al. Early myocardial strain changes during potentially cardiotoxic chemotherapy may occur as a result of reductions in left ventricular end-diastolic volume: The need to interpret left ventricular strain with volumes. Circulation 135 (2017), 2575–2577.
Melendez, G.C., Sukpraphrute, B., D'Agostino, R.B. Jr., et al. Frequency of left ventricular end-diastolic volume-mediated declines in ejection fraction in patients receiving potentially cardiotoxic cancer treatment. Am J Cardiol 119 (2017), 1637–1642.
Thavendiranathan, P., Poulin, F., Lim, K.D., et al. Use of myocardial strain imaging by echocardiography for the early detection of cardiotoxicity in patients during and after cancer chemotherapy: a systematic review. J Am Coll Cardiol 63 (2014), 2751–2768.
Jurcut, R., Wildiers, H., Ganame, J., et al. Strain rate imaging detects early cardiac effects of pegylated liposomal doxorubicin as adjuvant therapy in elderly patients with breast cancer. J Am Soc Echocardiogr 21 (2008), 1283–1289.
Motoki, H., Koyama, J., Nakazawa, H., et al. Torsion analysis in the early detection of anthracycline-mediated cardiomyopathy. Eur Heart J Cardiovasc Imaging 13 (2012), 95–103.
Poterucha, J.T., Kutty, S., Lindquist, R.K., et al. Changes in left ventricular longitudinal strain with anthracycline chemotherapy in adolescents precede subsequent decreased left ventricular ejection fraction. J Am Soc Echocardiogr 25 (2012), 733–740.
Mornos, C., Petrescu, L., Early detection of anthracycline-mediated cardiotoxicity: the value of considering both global longitudinal left ventricular strain and twist. Can J Physiol Pharmacol 91 (2013), 601–607.
Mitani, I., Jain, D., Joska, T.M., et al. Doxorubicin cardiotoxicity: prevention of congestive heart failure with serial cardiac function monitoring with equilibrium radionuclide angiocardiography in the current era. J Nucl Cardiol 10 (2003), 132–139.
Cardinale, D., Sandri, M.T., Role of biomarkers in chemotherapy-induced cardiotoxicity. Prog Cardiovasc Dis 53 (2010), 121–129.
Ky, B., Carver, J.R., Biomarker approach to the detection and cardioprotective strategies during anthracycline chemotherapy. Heart Fail Clin 7 (2011), 323–331.
Herman, E.H., Zhang, J., Lipshultz, S.E., et al. Correlation between serum levels of cardiac troponin-T and the severity of the chronic cardiomyopathy induced by doxorubicin. J Clin Oncol 17 (1999), 2237–2243.
Jensen, B.V., Skovsgaard, T., Nielsen, S.L., Functional monitoring of anthracycline cardiotoxicity: a prospective, blinded, long-term observational study of outcome in 120 patients. Ann Oncol 13 (2002), 699–709.
Swain, S.M., Whaley, F.S., Ewer, M.S., Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer 97 (2003), 2869–2879.
Schwartz, R.G., McKenzie, W.B., Alexander, J., et al. Congestive heart failure and left ventricular dysfunction complicating doxorubicin therapy. Seven-year experience using serial radionuclide angiocardiography. Am J Med 82 (1987), 1109–1118.
Nousiainen, T., Jantunen, E., Vanninen, E., et al. Early decline in left ventricular ejection fraction predicts doxorubicin cardiotoxicity in lymphoma patients. Br J Cancer 86 (2002), 1697–1700.
Perez, E.A., Suman, V.J., Davidson, N.E., et al. Effect of doxorubicin plus cyclophosphamide on left ventricular ejection fraction in patients with breast cancer in the North Central Cancer Treatment Group N9831 Intergroup Adjuvant Trial. J Clin Oncol 22 (2004), 3700–3704.
Ewer, M.S., Lenihan, D.J., Left ventricular ejection fraction and cardiotoxicity: is our ear really to the ground?. J Clin Oncol 26 (2008), 1201–1203.
Steinherz, L.J., Steinherz, P.G., Tan, C.T., et al. Cardiac toxicity 4 to 20 years after completing anthracycline therapy. JAMA 266 (1991), 1672–1677.
Ganame, J., Claus, P., Eyskens, B., et al. Acute cardiac functional and morphological changes after anthracycline infusions in children. Am J Cardiol 99 (2007), 974–977.
Lipshultz, S.E., Colan, S.D., Gelber, R.D., et al. Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. N Engl J Med 324 (1991), 808–815.
Perez, E.A., Suman, V.J., Davidson, N.E., et al. Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial. J Clin Oncol 26 (2008), 1231–1238.
Seidman, A., Hudis, C., Pierri, M.K., et al. Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol 20 (2002), 1215–1221.
Tan-Chiu, E., Yothers, G., Romond, E., et al. Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31. J Clin Oncol 23 (2005), 7811–7819.
Piccart-Gebhart, M.J., Procter, M., Leyland-Jones, B., et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353 (2005), 1659–1672.
Witteles, R.M., Biomarkers as predictors of cardiac toxicity from targeted cancer therapies. J Card Fail 22 (2016), 459–464.
Cobleigh, M.A., Vogel, C.L., Tripathy, D., et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 17 (1999), 2639–2648.
Seidman, A.D., Fornier, M.N., Esteva, F.J., et al. Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification. J Clin Oncol 19 (2001), 2587–2595.
Slamon, D.J., Leyland-Jones, B., Shak, S., et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344 (2001), 783–792.
Untch, M., Eidtmann, H., du Bois, A., et al. Cardiac safety of trastuzumab in combination with epirubicin and cyclophosphamide in women with metastatic breast cancer: results of a phase I trial. Eur J Cancer 40 (2004), 988–997.
Marty, M., Cognetti, F., Maraninchi, D., et al. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J Clin Oncol 23 (2005), 4265–4274.
Guarneri, V., Lenihan, D.J., Valero, V., et al. Long-term cardiac tolerability of trastuzumab in metastatic breast cancer: the M.D. Anderson Cancer Center experience. J Clin Oncol 24 (2006), 4107–4115.
Schairer, C., Mink, P.J., Carroll, L., et al. Probabilities of death from breast cancer and other causes among female breast cancer patients. J Natl Cancer Inst 96 (2004), 1311–1321.
Bradshaw, P.T., Stevens, J., Khankari, N., et al. Cardiovascular disease mortality among breast cancer survivors. Epidemiology 27 (2016), 6–13.
Maitland, M.L., Bakris, G.L., Black, H.R., et al. Initial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitors. J Natl Cancer Inst 102 (2010), 596–604.
Steingart, R.M., Bakris, G.L., Chen, H.X., et al. Management of cardiac toxicity in patients receiving vascular endothelial growth factor signaling pathway inhibitors. Am Heart J 163 (2012), 156–163.
Vaklavas, C., Lenihan, D., Kurzrock, R., et al. Anti-vascular endothelial growth factor therapies and cardiovascular toxicity: what are the important clinical markers to target?. Oncologist 15 (2010), 130–141.
Lenihan, D.J., Kowey, P.R., Overview and management of cardiac adverse events associated with tyrosine kinase inhibitors. Oncologist 18 (2013), 900–908.
Kerkela, R., Woulfe, K.C., Durand, J.B., et al. Sunitinib-induced cardiotoxicity is mediated by off-target inhibition of AMP-activated protein kinase. Clin Transl Sci 2 (2009), 15–25.
Khakoo, A.Y., Kassiotis, C.M., Tannir, N., et al. Heart failure associated with sunitinib malate: a multitargeted receptor tyrosine kinase inhibitor. Cancer 112 (2008), 2500–2508.
Chu, T.F., Rupnick, M.A., Kerkela, R., et al. Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet 370 (2007), 2011–2019.
Abdel-Qadir, H., Ethier, J.L., Lee, D.S., et al. Cardiovascular toxicity of angiogenesis inhibitors in treatment of malignancy: A systematic review and meta-analysis. Cancer Treat Rev 53 (2017), 120–127.
Maitland, M.L., Kasza, K.E., Karrison, T., et al. Ambulatory monitoring detects sorafenib-induced blood pressure elevations on the first day of treatment. Clin Cancer Res 15 (2009), 6250–6257.
Hamnvik, O.P., Choueiri, T.K., Turchin, A., et al. Clinical risk factors for the development of hypertension in patients treated with inhibitors of the VEGF signaling pathway. Cancer 121 (2015), 311–319.
Whelton, P.K., Carey, R.M., Aronow, W.S., et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol 71 (2018), 1269–1324.
McKay, R.R., Rodriguez, G.E., Lin, X., et al. Angiotensin system inhibitors and survival outcomes in patients with metastatic renal cell carcinoma. Clin Cancer Res 21 (2015), 2471–2479.
Catino, A.B., Hubbard, R.A., Chirinos, J.A., et al. Longitudinal assessment of vascular function with sunitinib in patients with metastatic renal cell carcinoma. Circ Heart Fail, 11, 2018, e004408.
Curwen, J.O., Musgrove, H.L., Kendrew, J., et al. Inhibition of vascular endothelial growth factor-a signaling induces hypertension: examining the effect of cediranib (recentin; AZD2171) treatment on blood pressure in rat and the use of concomitant antihypertensive therapy. Clin Cancer Res 14 (2008), 3124–3131.
Choueiri, T.K., Mayer, E.L., Je, Y., et al. Congestive heart failure risk in patients with breast cancer treated with bevacizumab. J Clin Oncol 29 (2011), 632–638.
Richards, C.J., Je, Y., Schutz, F.A., et al. Incidence and risk of congestive heart failure in patients with renal and nonrenal cell carcinoma treated with sunitinib. J Clin Oncol 29 (2011), 3450–3456.
Qi, W.X., Shen, Z., Tang, L.N., et al. Congestive heart failure risk in cancer patients treated with vascular endothelial growth factor tyrosine kinase inhibitors: a systematic review and meta-analysis of 36 clinical trials. Br J Clin Pharmacol 78 (2014), 748–762.
Narayan, V., Keefe, S., Haas, N., et al. Prospective evaluation of sunitinib-induced cardiotoxicity in patients with metastatic renal cell carcinoma. Clin Cancer Res 23 (2017), 3601–3609.
Schmidinger, M., Zielinski, C.C., Vogl, U.M., et al. Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 26 (2008), 5204–5212.
Motzer, R.J., Hutson, T.E., Cella, D., et al. Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N Engl J Med 369 (2013), 722–731.
Yoon, G.J., Telli, M.L., Kao, D.P., et al. Left ventricular dysfunction in patients receiving cardiotoxic cancer therapies are clinicians responding optimally?. J Am Coll Cardiol 56 (2010), 1644–1650.
Thakur, A., Witteles, R.M., Cancer therapy-induced left ventricular dysfunction: interventions and prognosis. J Card Fail 20 (2014), 155–158.
Bird, B.R., Swain, S.M., Cardiac toxicity in breast cancer survivors: review of potential cardiac problems. Clin Cancer Res 14 (2008), 14–24.
Lenihan, D.J., Cardinale, D., Cipolla, C.M., The compelling need for a cardiology and oncology partnership and the birth of the International CardiOncology Society. Prog Cardiovasc Dis 53 (2010), 88–93.
Hunt, S.A., ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). J Am Coll Cardiol 46 (2005), e1–e82.
Yancy, C.W., Jessup, M., Bozkurt, B., et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 62 (2013), e147–e239.
Ponikowski, P., Voors, A.A., Anker, S.D., et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 18 (2016), 891–975.
Howlett, J.G., Chan, M., Ezekowitz, J.A., et al. The Canadian Cardiovascular Society Heart Failure Companion: Bridging guidelines to your practice. Can J Cardiol 32 (2016), 296–310.
Lenihan, D.J., Hartlage, G., DeCara, J., et al. Cardio-oncology training: A proposal from the International Cardioncology Society and Canadian Cardiac Oncology Network for a New Multidisciplinary Specialty. J Card Fail 22 (2016), 465–471.
Cardinale, D., Colombo, A., Lamantia, G., et al. Anthracycline-induced cardiomyopathy: clinical relevance and response to pharmacologic therapy. J Am Coll Cardiol 55 (2010), 213–220.
Lipshultz, S.E., Lipsitz, S.R., Sallan, S.E., et al. Long-term enalapril therapy for left ventricular dysfunction in doxorubicin-treated survivors of childhood cancer. J Clin Oncol 20 (2002), 4517–4522.
Silber, J.H., Cnaan, A., Clark, B.J., et al. Enalapril to prevent cardiac function decline in long-term survivors of pediatric cancer exposed to anthracyclines. J Clin Oncol 22 (2004), 820–828.
Seymour, L., Bramwell, V., Moran, L.A., Use of dexrazoxane as a cardioprotectant in patients receiving doxorubicin or epirubicin chemotherapy for the treatment of cancer. The Provincial Systemic Treatment Disease Site Group. Cancer Prev Control 3 (1999), 145–159.
Smith, L.A., Cornelius, V.R., Plummer, C.J., et al. Cardiotoxicity of anthracycline agents for the treatment of cancer: systematic review and meta-analysis of randomised controlled trials. BMC Cancer, 10, 2010, 337.
Yu, A.F., Yadav, N.U., Eaton, A.A., et al. Continuous trastuzumab therapy in breast cancer patients with asymptomatic left ventricular dysfunction. Oncologist 20 (2015), 1105–1110.
Ewer, M.S., Vooletich, M.T., Durand, J.B., et al. Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment. J Clin Oncol 23 (2005), 7820–7826.
Cardinale, D., Ciceri, F., Latini, R., et al. Anthracycline-induced cardiotoxicity: A multicenter randomised trial comparing two strategies for guiding prevention with enalapril: The International CardioOncology Society-one trial. Eur J Cancer 94 (2018), 126–137.
Swain, S.M., Whaley, F.S., Gerber, M.C., et al. Delayed administration of dexrazoxane provides cardioprotection for patients with advanced breast cancer treated with doxorubicin-containing therapy. J Clin Oncol 15 (1997), 1333–1340.
Lipshultz, S.E., Rifai, N., Dalton, V.M., et al. The effect of dexrazoxane on myocardial injury in doxorubicin-treated children with acute lymphoblastic leukemia. N Engl J Med 351 (2004), 145–153.
Ponikowski, P., Voors, A.A., Anker, S.D., et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 37 (2016), 2129–2200.
Writing Committee Members Yancy, C.W., Jessup, M., et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation 128 (2013), e240–e327.
Cardinale, D., Colombo, A., Bacchiani, G., et al. Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy. Circulation 131 (2015), 1981–1988.
Suter, T.M., Procter, M., van Veldhuisen, D.J., et al. Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial. J Clin Oncol 25 (2007), 3859–3865.
Telli, M.L., Hunt, S.A., Carlson, R.W., et al. Trastuzumab-related cardiotoxicity: calling into question the concept of reversibility. J Clin Oncol 25 (2007), 3525–3533.
Qi, W.X., Lin, F., Sun, Y.J., et al. Incidence and risk of hypertension with pazopanib in patients with cancer: a meta-analysis. Cancer Chemother Pharmacol 71 (2013), 431–439.
Qi, W.X., He, A.N., Shen, Z., et al. Incidence and risk of hypertension with a novel multi-targeted kinase inhibitor axitinib in cancer patients: a systematic review and meta-analysis. Br J Clin Pharmacol 76 (2013), 348–357.
Ewer, M.S., Suter, T.M., Lenihan, D.J., et al. Cardiovascular events among 1090 cancer patients treated with sunitinib, interferon, or placebo: a comprehensive adjudicated database analysis demonstrating clinically meaningful reversibility of cardiac events. Eur J Cancer 50 (2014), 2162–2170.
Mayer, D.K., Nasso, S.F., Earp, J.A., Defining cancer survivors, their needs, and perspectives on survivorship health care in the USA. Lancet Oncol 18 (2017), e11–e18.
Miller, K.D., Siegel, R.L., Lin, C.C., et al. Cancer treatment and survivorship statistics, 2016. CA Cancer J Clin 66 (2016), 271–289.
Virani, S.A., Dent, S., Brezden-Masley, C., et al. Canadian Cardiovascular Society guidelines for evaluation and management of cardiovascular complications of cancer therapy. Can J Cardiol 32 (2016), 831–841.
Wang, X., Sun, C.L., Quinones-Lombrana, A., et al. CELF4 variant and anthracycline-related cardiomyopathy: A Children's Oncology Group genome-wide association study. J Clin Oncol 34 (2016), 863–870.
Wong, F.L., Bhatia, S., Landier, W., et al. Cost-effectiveness of the children's oncology group long-term follow-up screening guidelines for childhood cancer survivors at risk for treatment-related heart failure. Ann Intern Med 160 (2014), 672–683.
Lancellotti, P., Nkomo, V.T., Badano, L.P., et al. Expert consensus for multi-modality imaging evaluation of cardiovascular complications of radiotherapy in adults: a report from the European association of cardiovascular imaging and the american society of echocardiography. J Am Soc Echocardiogr 26 (2013), 1013–1032.
Hoppe, R.T., Advani, R.H., Ai, W.Z., et al. Hodgkin lymphoma version 1.2017, NCCN Clinical practice guidelines in oncology. J Natl Compr Canc Netw 15 (2017), 608–638.
Machann, W., Beer, M., Breunig, M., et al. Cardiac magnetic resonance imaging findings in 20-year survivors of mediastinal radiotherapy for Hodgkin's disease. Int J Radiat Oncol Biol Phys 79 (2011), 1117–1123.
Galvao, D.A., Taaffe, D.R., Spry, N., et al. Combined resistance and aerobic exercise program reverses muscle loss in men undergoing androgen suppression therapy for prostate cancer without bone metastases: a randomized controlled trial. J Clin Oncol 28 (2010), 340–347.
Speck, R.M., Courneya, K.S., Masse, L.C., et al. An update of controlled physical activity trials in cancer survivors: a systematic review and meta-analysis. J Cancer Surviv 4 (2010), 87–100.
Schmitz, K.H., Courneya, K.S., Matthews, C., et al. American College of Sports Medicine roundtable on exercise guidelines for cancer survivors. Med Sci Sports Exerc 42 (2010), 1409–1426.
Courneya, K.S., Segal, R.J., Mackey, J.R., et al. Effects of aerobic and resistance exercise in breast cancer patients receiving adjuvant chemotherapy: a multicenter randomized controlled trial. J Clin Oncol 25 (2007), 4396–4404.
Rock, C.L., Doyle, C., Demark-Wahnefried, W., et al. Nutrition and physical activity guidelines for cancer survivors. CA Cancer J Clin 62 (2012), 243–274.
Pekmezi, D.W., Demark-Wahnefried, W., Updated evidence in support of diet and exercise interventions in cancer survivors. Acta Oncol 50 (2011), 167–178.
Chlebowski, R.T., Aiello, E., McTiernan, A., Weight loss in breast cancer patient management. J Clin Oncol 20 (2002), 1128–1143.
Protani, M., Coory, M., Martin, J.H., Effect of obesity on survival of women with breast cancer: systematic review and meta-analysis. Breast Cancer Res Treat 123 (2010), 627–635.
Meyerhardt, J.A., Ma, J., Courneya, K.S., Energetics in colorectal and prostate cancer. J Clin Oncol 28 (2010), 4066–4073.
Wright, M.E., Chang, S.C., Schatzkin, A., et al. Prospective study of adiposity and weight change in relation to prostate cancer incidence and mortality. Cancer 109 (2007), 675–684.
Siegel, E.M., Ulrich, C.M., Poole, E.M., et al. The effects of obesity and obesity-related conditions on colorectal cancer prognosis. Cancer Control 17 (2010), 52–57.
Kroenke, C.H., Chen, W.Y., Rosner, B., et al. Weight, weight gain, and survival after breast cancer diagnosis. J Clin Oncol 23 (2005), 1370–1378.
Meyerhardt, J.A., Niedzwiecki, D., Hollis, D., et al. Impact of body mass index and weight change after treatment on cancer recurrence and survival in patients with stage III colon cancer: findings from Cancer and Leukemia Group B 89803. J Clin Oncol 26 (2008), 4109–4115.
Look, A.R.G., Wing, R.R., Long-term effects of a lifestyle intervention on weight and cardiovascular risk factors in individuals with type 2 diabetes mellitus: four-year results of the Look AHEAD trial. Arch Intern Med 170 (2010), 1566–1575.
Kroenke, C.H., Fung, T.T., Hu, F.B., et al. Dietary patterns and survival after breast cancer diagnosis. J Clin Oncol 23 (2005), 9295–9303.
Kwan, M.L., Weltzien, E., Kushi, L.H., et al. Dietary patterns and breast cancer recurrence and survival among women with early-stage breast cancer. J Clin Oncol 27 (2009), 919–926.
Meyerhardt, J.A., Niedzwiecki, D., Hollis, D., et al. Association of dietary patterns with cancer recurrence and survival in patients with stage III colon cancer. JAMA 298 (2007), 754–764.
Puzanov, I., Diab, A., Abdallah, K., et al. Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group. J Immunother Cancer, 5, 2017, 95.
Brahmer, J.R., Lacchetti, C., Schneider, B.J., et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol 36 (2018), 1714–1768.
Haanen, J., Carbonnel, F., Robert, C., et al. Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 28 (2017), iv119–iv142.
Johnson, D.B., Balko, J.M., Compton, M.L., et al. Fulminant myocarditis with combination immune checkpoint blockade. N Engl J Med 375 (2016), 1749–1755.
Mahmood, S.S., Fradley, M.G., Cohen, J.V., et al. Myocarditis in patients treated with immune checkpoint inhibitors. J Am Coll Cardiol 71 (2018), 1755–1764.
Neilan, T.G., Rothenberg, M.L., Amiri-Kordestani, L., et al. Myocarditis associated with immune checkpoint inhibitors: An expert consensus on data gaps and a call to action. Oncologist 23 (2018), 874–878.
Anquetil, C., Salem, J.E., Lebrun-Vignes, B., et al. Immune checkpoint inhibitor-associated myositis. Circulation 138 (2018), 743–745.
Lyon, A.R., Yousaf, N., Battisti, N.M.L., et al. Immune checkpoint inhibitors and cardiovascular toxicity. Lancet Oncol 19 (2018), e447–e458.
Moslehi, J.J., Salem, J.E., Sosman, J.A., et al. Reporting of immune checkpoint inhibitor-associated myocarditis - Authors' reply. Lancet 392 (2018), 384–385.
Moslehi, J.J., Salem, J.E., Sosman, J.A., et al. Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis. Lancet, 391, 2018, 933.
Lee Chuy, K., Oikonomou, E.K., Postow, M.A., et al. Myocarditis surveillance in patients with advanced melanoma on combination immune checkpoint inhibitor therapy: The Memorial Sloan Kettering Cancer Center experience. Oncologist 24 (2019), e196–e197.
Ball, S., Ghosh, R.K., Wongsaengsak, S., et al. Cardiovascular toxicities of immune checkpoint inhibitors: JACC review topic of the week. J Am Coll Cardiol 74 (2019), 1714–1727.
Lefrak, E.A., Pitha, J., Rosenheim, S., et al. A clinicopathologic analysis of Adriamycin cardiotoxicity. Cancer 32 (1973), 302–314.
Lancellotti, P., Suter, T.M., Lopez-Fernandez, T., et al. Cardio-Oncology Services: rationale, organization, and implementation. Eur Heart J 40 (2019), 1756–1763.
Ganatra, S., Hayek, S.S., Cardio-oncology for GenNext: a missing piece of the training puzzle. J Am Coll Cardiol 71 (2018), 2977–2981.
Hayek, S.S., Ganatra, S., Lenneman, C., et al. Preparing the cardiovascular workforce to care for oncology patients: JACC Review Topic of the Week. J Am Coll Cardiol 73 (2019), 2226–2235.